Antibodies to VLA-1

Details Antibodies to VLA-1 Antibodies to VLA-1

2008-04-15

2008-04-15

Haddad, Maher M. (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C530S388220, C530S387300, C435S326000

Reexamination Certificate

active

07358054

ABSTRACT:
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

REFERENCES:
patent: 5391481 (1995-02-01), Chess et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5798230 (1998-08-01), Bornkamm et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5855888 (1999-01-01), Nishida et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6016159 (2000-01-01), Faris
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6127524 (2000-10-01), Casipit et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6326403 (2001-12-01), Hölzemann et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 843 961 (1998-05-01), None
patent: 08-131185 (1996-05-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 99/61040 (1999-12-01), None
patent: WO 00/20459 (2000-04-01), None
patent: WO 00/72881 (2000-12-01), None
patent: WO 01/73444 (2001-10-01), None
patent: WO 01/96365 (2001-12-01), None
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4.
R. Briesewitz et al., “Expression of Native and Truncated Forms of the Human Integrin α1 Subunit,”J. Bio. Chem., 268:2989-2996 (1993).
A. R. de Fougerolles et al., “Regulation of Inflammation by Collagen-Binding Integrins α1β1 and α2β1 in Models of Hypersensitivity and Arthritis,”J. Clin. Invest., 105:721-729 (2000).
M. Fabbri et al., “A Functional Monoclonal Antibody Recognizing the Human alpha1-Integrin I-Domain,”Tissue Antigens, 48:47-51 (1996).
I. Bank et al., “Analysis of Recombinant Human α1 Integrin I-Domain with a Function-Blocking Monoclonal Antibody 1B3.1,”Isr. Med. Assoc. J., 2:19-20 (2000).
S.C.G. Brezinsky et al., “A Simple Method for Enriching Populations of Transfected CHO Cells for Cells of Higher Specific Productivity,”J. Immunol. Methods, 277:141-155 (2003).
H. T. Cook et al., “Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis,”Am. J. Pathol., 161:1265-1272 (2002).
T. O. Fischmann et al., “Crystallographic Refinement of the Three-Dimensional Structure of the FabD1.3-Lysozyme Complex at 2.5-Å Resolution,”J. Biol. Chem., 266:12915-12920 (1991).
M. A. Holmes et al., “Conformational Correction Mechanisms Aiding Antigen Recognition by a Humanized Antibody,”J. Exp. Med., 187:479-485 (1998).
A. Ianaro et al., “Anti-Very Late Antigen-1 Monoclonal Antibody Modulates the Development of Secondary Lesion and T-Cell Response in Experimental Arthritis,”Lab. Invest., 80:73-80 (2000).
M. Karpusas et al., “Crystal Structure of the α1β1 Integrin I Domain in Complex with an Antibody Fab Fragment,”J. Mol. Biol., 327:1031-1041 (2003).
Y. Li et al., “Three-Dimensional Structures of the Free and Antigen-Bound Fab from Monoclonal Antilysozyme Antibody HyHEL-63,”Biochemistry, 39:6296-6309 (2000).
N. S. Sampson et al., “Global Gene Expression Analysis Reveals a Role for the α1Integrin in Renal Pathogenesis,”J. Biol. Chem., 276:34182-34188 (2001).
E.T. Baldwin et al.,“Cation Binding to the Integrin CD11b I Domain and Activation Model Assessment,”Structure,6:923-935 (1998).
R. Briesewitz et al., “Expression of Native and Truncated Forms of the Human Integrin α1Subunit,”J. Biol. Chem., 268:2989-2996 (1993).
P. Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992).
C. Chothia et al., “Conformations of Immunoglobulin Hypervariable Regions,”Nature, 342:877-883 (1989).
M.S. Co et al., “Humanized Antibodies for Antiviral Therapy,”Proc. Nat. Acad. Sci. USA, 88:2869-2873 (1991).
A.L. Corbi et al., “The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) α Subunit,”J. Biol. Chem., 263:12403-12411 (1988).
A.L. Corbi et al., “cDNA Cloning and Complete Primary Structure of the α Subunit of a Leukocyte Adhesion Glycoprotein, P150,95,”EMBO J., 6:4023-4028 (1987).
D. Cosgrove, et al., “Integrin α1β1 and Transforming Growth Factor-β1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy,”Am. J. Path., 157:1649-1659 (2000).
D.R. Davies and G.H. Cohen, “Interactions of Protein Antigens with Antibodies,”Proc. Natl. Acad. Sci. USA, 93:7-12 (1996).
A.R. de Fougerolles et al., “Global Expression Analysis of Extracellular Matrix-Integrin Interactions in Monocytes,”Immunity, 13:749-758 (2000).
C.P. Edwards et al., “Identification of Amino Acids in the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecule-1 (ICAM-1)”,J. Biol. Chem., 270, 12635-12640 (1995).
C. Eigenbrot et al., “X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2Antibody 4D5 and Comparison with Molecular Modeling,”J. Mol. Biol., 229:969-995 (1993).
J. Emsley et al., “Structural Basis of Collagen Recognition by Integrin α2β1,”Cell, 100:47-56 (2000).
J. Emsley et al., “Crystal Structure of the I Domain from Integrin α2β1,”J. Biol. Chem., 272:28512-28517 (1997).
J. Foote and G. Winter, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol., 224:487-499 (1992).
A.A. Gaspari and S.I. Katz, “Contact Hypersensitivity,”Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, New York. Section 4.2.1-4.2.5 (1991).
P.J. Gotwals et al., “Divalent Cations Stabilize the α1β1 Integrin I Domain,”Biochemistry, 38:8280-8288 (1999).
P.J. Gotwals et al., “The α1β1 Integrin Is Expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization,”J. Clin. Invest., 97:2469-2477 (1996).
M.H. Grayson et al., αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1),J. Exp. Med., 188:2187-2191 (1988).
L.L. Green et al., “Antigen-specific Human Monoclonal Antibodies From Mice Engineered With Human Ig Heavy and Light Chain YACs,”Nature Genetics, 7:13-21 (1994).
M.E. Hemler et al., “Very Late Activation Antigens on Rheumatoid Synovial Fluid T Lymphocytes: Association with Stages of T Cell Activation,”J. Clin. Invest., 78:696-702 (1986).
M.E. Hemler et al., “VLA-1: A T Cell Surface Antigen which Defines a Novel Late Stage of Human T Cell Activation,”Eur. J. Immunol., 15:502-508 (1985).
C. Huang and B.D. Stollar, “A Majority of Ig H Chain cDNA of Normal Human Adult Blood Lymphocytes Resembles cDNA for Fetal Ig and Natural Autoantibodies,”J. Immunol., 151:5290-5300 (1993).
B. Hurtrel et al., “Differen

Affiliated with

Also associated with

Rating

Antibodies to VLA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to VLA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to VLA-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2755023